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ECONOMIC EVALUATION OF TREATMENT STRATEGIES FOR LATE-
PRESENTATION ACUTE ISCHEMIC STROKE
Nam J, O’Reilly D
PATH Research Institute, McMaster University, Hamilton, ON, Canada
OBJECTIVES: For late-presentation ischemic stroke patients, economic evidence
comparing all currently employed treatment strategies is lacking. We conducted
an economic evaluation comparing best medical treatment to intravenous throm-
bolysis, intra-arterial thrombolysis and mechanical thrombectomy for these
patients. METHODS: A probabilistic economic model was designed from the per-
spective of a government payer to calculate the lifetime incremental costs and
quality adjusted life years (QALYs) for each treatment compared to best medical
treatment. Effectiveness data were extracted from randomized trials, where pos-
sible, and discharge disposition fromOntario stroke registries. Inpatient costswere
taken from the Ontario Case Costing Initiative, professional fees from the Ontario
Schedule of Benefits for Physician Services and other costs from an Ontario cost of
stroke study. Costs were presented in 2011 Canadian dollars. RESULTS: Expected
incremental QALYs over best medical treatment were 0.02, 0.16 and 0.27 for intra-
venous thrombolysis, intra-arterial thrombolysis and mechanical thrombectomy,
respectively, while the expected incremental costs were $1,986; $4,336 and $4,058,
respectively. Expected incremental QALYs and costs showed that both intravenous
thrombolysis and intra-arterial thrombolysis were extendedly dominated. Me-
chanical thrombectomy had an incremental cost-effectiveness ratio of $14,790/
QALY. At a willingness-to-pay threshold of $50,000/QALY, mechanical thrombec-
tomy and intra-arterial thrombolysis had 70% and 30% likelihood of being cost-
effective, respectively. Intravenous thrombolysis had the lowest probability of
being cost-effective across all willingness-to-pay thresholds ($0-$200,000/QALY).
CONCLUSIONS: Intravenous thrombolysis in late-presentation stroke patients
may not be a cost-effective treatment strategy. Endovascular approaches such as
intra-arterial thrombolysis and especially mechanical thrombectomy may lead to
an economic benefit, though more evidence is needed to reduce considerable de-
cision uncertainty.
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DID MASSACHUSETTS HEALTH REFORM LOWER HOSPITAL INPATIENT COST?
Wong H, Karaca Z
Agency for Healthcare Research and Quality (AHRQ), Rockville, MD, USA
OBJECTIVES: This paper estimates the impact of Massachusetts healthcare reform
on the cost of inpatient visits by employing several methodological approaches
using panel data. METHODS: The Healthcare Cost and Utilization Project (HCUP)
2005-2009 State Inpatient Databases (SID) for Massachusetts were used in this
analysis. The SID provide detailed diagnoses and procedures, total charges and
patient demographics. Our key covariate of interest is MA enrollment and the total
costs associated with each hospital visit. To obtain costs, we applied hospital spe-
cific HCUP cost-to-charge ratios. We adjusted these costs with the CMS area wage
index. We obtained information about hospital characteristics using the American
Hospital Association Annual Survey Database; and county level information from
the Area Resource File. We develop a baseline cost model with risk-adjustments to
estimate the impact of Massachusetts health reform on the total costs of inpatient
visits. Our methodological approach controls for patients heterogeneity, and re-
duces biases resulting from aggregation over patients over time. To assess the
robustness of our baseline results, we conducted several empirical estimations and
tested their significance. First, we estimated the baseline cost model with pooled
ordinary linear regressions (OLS). Next, we estimated the baseline cost model with
random effect panel regression. We performed the Lagrange Multiplier (Breusch
and Pagan 1980) test and found that randomeffect panel data estimates are favored
over pooled OLS estimates. Next, we estimated our baseline cost model with a
fixed-effect panel regression. We also performed the Hausman specification test
(Hausman 1978), which indicated that the fixed effect model was appropriate com-
pared to random effect model. RESULTS: Our estimates show that Massachusetts
health reform decreased the hospital inpatient cost per visit at least by $120 when
individual heterogeneity and risk-adjustments were controlled. CONCLUSIONS:
We found that Massachusetts health reform decreased the average cost of the
hospital inpatient visits.
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OBJECTIVES: To evaluate the association of allergic rhinitis (AR) with asthma ex-
acerbations and healthcare costs of asthma patients.METHODS:Newly diagnosed
patients 12-64 years of age with 2 asthma diagnoses, or 1 diagnosis and 1 asth-
ma-related prescription claim, during the period 1/1/2008-3/31/2011, continuously
eligible for 12 months before and 24 months after index asthma diagnosis were
identified from a privately-insured claims database (N14,000,000). The index date
was defined as the date one year after the index asthma diagnosis, baseline period
as 12 months before, and study period as 12 months after the index date. Two
cohorts were selected from the sample: asthma-only (without any AR diagnosis);
and asthmaAR (with 1 AR diagnosis and 1 intranasal corticosteroid claim
during baseline). Descriptive analyses compared demographic characteristics,
co-morbidities, healthcare costs (medical service and prescription drug costs)
inflated to 2010 dollars, and asthma exacerbations (defined as either an inpa-
tient or emergency department visit with asthma diagnosis or use of oral cor-
ticosteroid). Multivariate analyses adjusting for baseline differences were used
to estimate risk-adjusted asthma exacerbations and costs. RESULTS:
AsthmaAR patients(n3,716) had similar mean age and gender distribution but
higher proportions of comorbidities(e.g., sinusitis, sleep apnea) compared with
asthma-only patients(n8,547). During the study period, asthmaAR patients had
significantly higher proportion of asthma exacerbations(29.5% vs. 20.6%, p.0001),
possibly due to higher oral corticosteroid use(27.8% vs. 18.5%, p.0001), and higher
mean number of asthma-related outpatient/other visits(7.1 vs. 3.4, p.0001).
AsthmaAR patients had significantly higher healthcare costs($6,833 vs. $6,137,
p.0001), due to higher drug costs($2,136 vs. $1,396, p.0001), higher asthma-re-
lated costs($744 vs. $439, p.0001), and higher asthma-related drug costs($492 vs.
$250, p.0001), than asthma-only patients. Risk-adjusted asthma exacerbations
and costs were also higher for asthmaAR patients. CONCLUSIONS: In this anal-
ysis, patients with asthmaAR had significantly higher proportion of asthma-re-
lated exacerbations and higher healthcare costs compared with asthma-only pa-
tients.
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OBJECTIVES: Greater market availability and high per unit costs make biopharma-
ceuticals one of the fastest growing areas of health care spending. As a result,
policymakers are increasingly questioning whether they provide value for money.
The purpose of this study was to examine the cost-utility literature to compare the
value of biopharmaceuticals with conventional pharmaceutical and non-pharma-
ceutical interventions. METHODS: The Tufts Medical Center Cost-Effectiveness
Analysis Registry (www.cearegistry.org), which contains detailed information on
over 2300 cost-utility analyses (CUAs), was used for the analysis. Articles for biop-
harmaceuticals were identified using the Biotechnology Database from the Tufts
Center for the Study of Drug Development. The characteristics and study quality of
all articles published between 1976 and 2009 were compared across the three cat-
egories of interventions. The distribution of cost-utility ratios, weighted by the
number of published ratios in the article, for each intervention category and se-
lected diseases studied were also compared. RESULTS: Studies of biopharmaceu-
ticals comprised 11% of the 2383 studies included in the Registry, making them the
sixth largest category. Overall characteristics of biopharmaceutical articles were
similar to other CUAs, yet they had slightly better methodological quality. The
weighted median ratio for biopharmaceuticals ($15,412) was less favorable (i.e.,
higher) than those of conventional pharmaceuticals ($7,095) and most other types
of health interventions ($9,284). Ratios for biopharmaceutical cancer, rheumato-
logic, and neurological therapies were also significantly more likely to be greater
than the overall median of $9041 as compared with other interventions. Despite
these results, the wide range of biopharmaceutical ratios suggestsmany neverthe-
less provide value for money. CONCLUSIONS: Biopharmaceuticals occupy a small
yet increasing role in the cost-utility literature. While, in aggregate, they are less
favorable than most other types of treatments for a number of diseases, the data
suggest that many individual biopharmaceutical therapies are cost-effective.
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CMS’S USE OF COST-EFFECTIVENESS EVIDENCE IN NCDS FOR PREVENTION
Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: The U.S. Centers for Medicare and Medicaid Service’s (CMS’s) stated
policy is that it does not use cost-effectiveness evidence in National Coverage
Determinations (NCDs). This position appeared to be reinforced in the recent U.S.
Patient Protection and Affordable Care Act (PPACA) which, while not explicitly
prohibiting the use of cost-effectiveness evidence, barred the use of cost-per QALY
thresholds in coverage decisions. The objective of this study is to reviewCMSNCDs
made since the enactment of PPACA (March 23, 2010) to determine whether and
how CMS has used cost-effectiveness evidence in its decision-making.METHODS:
We reviewed the decision memorandum for each NCD from March 23, 2010,
through December 2011. We documented any mention of cost-effectiveness evi-
dence. On occasions when cost-effectiveness evidence was used or cited in CMS’s
review, we reviewed the decision memorandum to identify the legislative author-
ity cited. RESULTS: Since March 23, 2010, CMS have made 18 NCDs. Cost-effective-
ness evidencewas used only in the 4 of the 18 NCDs pertaining to preventative care
(i.e., in the 14NCDs pertaining to non-preventative care, cost-effectivenesswas not
mentioned). In two instances, cost-utility studies (reporting cost-per QALY ratios)
featured in CMS’s review. In the remaining two instances, cost-effectiveness was
reported using “cost-per additional depression free day” and “cost-per case
treated”. A cost-per QALY threshold was not discussed in any decision memo. In
each instance, the legislative authority used for the inclusion of cost-effectiveness
evidence was the Medicare Improvement for Patients and Providers Act (MIPPA) of
2008 (which grants CMS authority to “conduct an assessment of the relation between pre-
dicted outcomes and the expenditures.”) CONCLUSIONS: The findings suggest that CMS
is routinely considering cost-effectiveness evidence in NCDs for preventative care.
Consistent with the PPACA legislation, a cost-per QALY threshold was not used.
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